Viatris Deadline Today: Rosen Law Firm Urges Viatris Inc. (NASDAQ: VTRS) Stockholders With Large Losses to Contact the Firm for Information About Their Rights
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of Viatris Inc. (NASDAQ: VTRS) securities between August 8, 2024 and February 26, 2025, both dates inclusive (the 'Class Period'). Viatris describes itself as a 'global healthcare company, which engages in the provision of healthcare and pharmaceutical products.'
For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653.
The Allegations: Rosen Law Firm is Investigating the Allegations that Viatris Inc. (NASDAQ: VTRS) Misled Investors Regarding its Business Operations.
According to the lawsuit, during the Class Period, defendants provided investors with material information concerning the failed inspection of Viatris' Indore, India facility. Defendants' statements, albeit made months after the initial inspection and Defendants' initiation of remediation efforts included, among other things, the disclosure of the FDA's issuance of a warning letter and import alert which would prevent Viatris from shipping eleven products from the Indore facility, though four of such were exempt from the limitations (the 'Warning Letter'). Defendants routinely referred to the impact of the Warning Letter as a mere 'minor headwind' for Viatris.
Further, defendants provided these disclosures to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state impact of the Warning Letter on Viatris' financials. Notably, defendants did not disclose precisely when the inspection occurred, how long the remediation efforts had been implemented, or the financial impact of the existing and continued remediation efforts. Defendants further notably failed to disclose which products were subject to the FDA Warning Letter, which products were subject to exemptions, and the significance of the restricted products with respect to Viatris' existing financials and future projections, and for which Viatris believed it would obtain exemptions. Such statements, absent these material facts, caused Plaintiff and other shareholders to purchase Viatris' securities at artificially inflated prices. When the true details entered the market, the lawsuit claims that investors suffered damages.
What Now: You may be eligible to participate in the class action against Viatris Inc. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by June 3, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Simulations Plus Releases ADMET Predictor® 13
Expanded functionality and advanced AI/ML capabilities deliver faster, more accurate predictions and streamline enterprise deployment RESEARCH TRIANGLE PARK, N.C., June 05, 2025--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced the release of ADMET Predictor® 13, its flagship machine learning (ML) modeling platform for the design, optimization, and selection of new molecules during various stages of drug discovery. ADMET Predictor 13 features advancements in three main areas: First-to-invent advantage: clients can harness enhanced high-throughput PBPK (HT-PBPK) simulations—powered by GastroPlus®—combined with the upgraded AI-driven drug design (AIDD) engine to enable faster, smarter decision-making at the intersection of chemistry and pharmacokinetics. Elevated predictive power: ADMET Predictor 13 offers an expanded suite of next-gen ADMET models, built with updated AI science and premium datasets, which boost accuracy across key endpoints and reinforce scientific rigor and validation. Enterprise-ready automation: with extended APIs, Python scripting support, and IT-friendly deployment capabilities, ADMET Predictor 13 delivers the automation and scalability required by today's data-centric R&D teams. "ADMET Predictor has long been the standard for discovery modeling platforms in the pharmaceutical space," said David Miller, Vice President of Cheminformatics of Simulations Plus. "Before artificial intelligence and machine learning became industry buzzwords, ADMET Predictor was already leveraging these technologies to help our clients design and optimize new compounds. By tightly integrating mechanistic simulation with AI/ML and wrapping it in a powerful, customizable software platform that can be seamlessly deployed into existing workflows, we are now making predictions more accurate and easier to access for our clients around the world." Learn more about ADMET Predictor 13 or request a demo. About Simulations Plus, Inc. With more than 25 years of experience serving clients globally, Simulations Plus stands as a premier provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. Our comprehensive biosimulation solutions integrate artificial intelligence/machine learning (AI/ML), physiologically based pharmacokinetics, physiologically based biopharmaceutics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. We also deliver simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Our cutting-edge technology is licensed and utilized by leading pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at Follow us on LinkedIn | X | YouTube. Environmental, Social, and Governance (ESG) We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our 2024 ESG update. Forward-Looking Statements Except for historical information, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties. Words like "believe," "will", "can", "believe", "expect," "anticipate" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) mean that these are our best estimates as of this writing, but there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Forward looking statements contained in this press release include, but are not limited to, statements about expectations for the second half of 2025 and anticipated projections for fiscal year 2025. Factors that could cause or contribute to such differences include, but are not limited to: our ability to integrate our ALI and MC business units, our ability to meet our stated guidance, our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, market conditions, macroeconomic factors, and a sustainable market. Further information on our risk factors is contained in our quarterly, annual and current reports and filed with the U.S. Securities and Exchange Commission. View source version on Contacts Financial Profiles Lisa Fortuna310-622-8251slp@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25 minutes ago
- Yahoo
AMD Acquires Another Company To Expand AI Arsenal
Advanced Micro Devices, Inc (NASDAQ:AMD) on Wednesday announced the acquisition of Brium, a team of compiler and AI software experts with deep expertise in machine learning, AI inference, and performance optimization. The financial terms of the transaction remain undisclosed. Brium brings advanced software capabilities that strengthen AMD's ability to deliver highly optimized AI solutions across the entire stack. Their work in compiler technology, model execution frameworks, and end-to-end AI inference optimization will play a key role in enhancing the efficiency and flexibility of AMD's AI acquisition marks the latest in a series of targeted investments, following AMD's acquisitions of Silo AI, and Mipsology, that boosts its ability to support the open-source software ecosystem and deliver optimized performance on its hardware. Last week, AMD announced the acquisition of Enosemi, a move to accelerate co-packaged optics innovation for AI systems. The financial terms of the deal remain undisclosed. AMD held $6.06 billion in cash and equivalents as of March 29, 2025. AMD stock plunged 29% in the last 12 months as it grappled with intensifying rivalry from Nvidia Corp (NASDAQ:NVDA), a cooling tech rally, and the Trump administration's tariff policies. AMD reported first-quarter revenue of $7.44 billion, up 36%, beating analyst estimates of $7.13 billion. The chipmaker reported first-quarter adjusted earnings of 96 cents per share, beating analyst estimates of 94 cents per share. AMD expects second-quarter revenue of approximately $7.4 billion, plus or minus $300 million. Analysts are currently forecasting second-quarter revenue of $7.24 billion. Price Action: AMD stock is trading higher by 0.42% to $119.08 premarket at last check Thursday. Read Next:Photo by jamesonwu1972 via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? ADVANCED MICRO DEVICES (AMD): Free Stock Analysis Report This article AMD Acquires Another Company To Expand AI Arsenal originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
33 minutes ago
- Business Wire
Simulations Plus Releases ADMET Predictor® 13
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) ('Simulations Plus'), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced the release of ADMET Predictor® 13, its flagship machine learning (ML) modeling platform for the design, optimization, and selection of new molecules during various stages of drug discovery. ADMET Predictor 13 features advancements in three main areas: First-to-invent advantage: clients can harness enhanced high-throughput PBPK (HT-PBPK) simulations—powered by GastroPlus®—combined with the upgraded AI-driven drug design (AIDD) engine to enable faster, smarter decision-making at the intersection of chemistry and pharmacokinetics. Elevated predictive power: ADMET Predictor 13 offers an expanded suite of next-gen ADMET models, built with updated AI science and premium datasets, which boost accuracy across key endpoints and reinforce scientific rigor and validation. Enterprise-ready automation: with extended APIs, Python scripting support, and IT-friendly deployment capabilities, ADMET Predictor 13 delivers the automation and scalability required by today's data-centric R&D teams. 'ADMET Predictor has long been the standard for discovery modeling platforms in the pharmaceutical space,' said David Miller, Vice President of Cheminformatics of Simulations Plus. 'Before artificial intelligence and machine learning became industry buzzwords, ADMET Predictor was already leveraging these technologies to help our clients design and optimize new compounds. By tightly integrating mechanistic simulation with AI/ML and wrapping it in a powerful, customizable software platform that can be seamlessly deployed into existing workflows, we are now making predictions more accurate and easier to access for our clients around the world.' Learn more about ADMET Predictor 13 or request a demo. About Simulations Plus, Inc. With more than 25 years of experience serving clients globally, Simulations Plus stands as a premier provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. Our comprehensive biosimulation solutions integrate artificial intelligence/machine learning (AI/ML), physiologically based pharmacokinetics, physiologically based biopharmaceutics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. We also deliver simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Our cutting-edge technology is licensed and utilized by leading pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at Follow us on LinkedIn | X | YouTube. Environmental, Social, and Governance (ESG) We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our 2024 ESG update. Forward-Looking Statements Except for historical information, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties. Words like 'believe,' 'will', 'can', 'believe', 'expect,' 'anticipate' and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) mean that these are our best estimates as of this writing, but there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Forward looking statements contained in this press release include, but are not limited to, statements about expectations for the second half of 2025 and anticipated projections for fiscal year 2025. Factors that could cause or contribute to such differences include, but are not limited to: our ability to integrate our ALI and MC business units, our ability to meet our stated guidance, our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, market conditions, macroeconomic factors, and a sustainable market. Further information on our risk factors is contained in our quarterly, annual and current reports and filed with the U.S. Securities and Exchange Commission.
